30 subjects now randomised in Lynovex CARE-CF-1 trial
NovaBiotics Ltd (NovaBiotics) this week reached a key milestone in its CARE-CF-1 clinical study (NBTCS-02) investigating oral Lynovex® as an adjunct therapy in Cystic Fibrosis (CF) infectious exacerbations with a quarter of patients now randomised. Subjects have now been dosed in several sites across the UK, US & Italy.
The randomised, placebo controlled double blind study follows promising preliminary Phase IIa data for NovaBiotics’ orphan drug candidate. The current trial aims to assess the benefits of oral Lynovex®, the hard gel capsule form of the drug, as adjunct therapy to standard of care antibiotic and other interventions in CF infectious exacerbations.